<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964404</url>
  </required_header>
  <id_info>
    <org_study_id>D14061</org_study_id>
    <secondary_id>1R01DA034699-01A1</secondary_id>
    <nct_id>NCT01964404</nct_id>
  </id_info>
  <brief_title>Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?</brief_title>
  <official_title>Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Medical School (HMS and HSDM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nathan Kline Institute for Psychiatric Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this translational research proposal, based on our formulation, we seek to confirm and&#xD;
      expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid&#xD;
      agonist dronabinol, given in low dose to patients with schizophrenia and co-occurring&#xD;
      cannabis use disorder, will in fact ameliorate the brain reward circuit dysregulation in&#xD;
      these patients and, thereby, provide evidence in support of the role of cannabis as a&#xD;
      &quot;self-medication&quot; agent for them.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Substance use disorders are strikingly common in patients with schizophrenia and contribute&#xD;
      to its morbidity and cost to society. We have proposed a neurobiological formulation&#xD;
      suggesting that cannabis and other substance use in these patients may ameliorate a&#xD;
      dysfunction in the brain reward circuit(thus serving a &quot;self-medication&quot; function), while&#xD;
      also worsening the symptoms and course of schizophrenia.&#xD;
&#xD;
      In this translational research proposal, based on our formulation, we seek to confirm and&#xD;
      expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid&#xD;
      agonist dronabinol, given in low dose to patients with schizophrenia and co-occurring&#xD;
      cannabis use disorder, will in fact ameliorate the brain reward circuit dysregulation in&#xD;
      these patients and, thereby, provide evidence in support of the role of cannabis as a&#xD;
      &quot;self-medication&quot; agent for them. Also, by also testing the full range of effects produced by&#xD;
      dronabinol (effects on brain reward circuitry assessed with task-based function MRI and&#xD;
      resting state connectivity), as well as on reward responsiveness, mood, craving, cognition,&#xD;
      psychiatric and extrapyramidal symptoms), we will provide clues as to whether dronabinol&#xD;
      should be tried in low doses as an adjunctive agent (with an antipsychotic medication) to&#xD;
      limit cannabis use in patients with schizophrenia.&#xD;
&#xD;
      This study will involve 8 groups of 25 participants each. Groups 1-3 will have diagnoses of&#xD;
      schizophrenia and cannabis use disorder; Group 4 will have schizophrenia only, Groups 5-7&#xD;
      will have cannabis use disorder only and Group 8 will be healthy control participants.&#xD;
      Following screening and baseline neuropsychiatric testing, participants will have two tests&#xD;
      days (T1 and T2) that will include task-based functional MRI, including assessment of resting&#xD;
      state connectivity, and measuring a number of other parameters including reward&#xD;
      responsiveness, mood, craving, symptoms and cognition. The assessments at T1 will be&#xD;
      virtually the same for all groups. At T2 Groups 1-3, and Groups 5-7 will be randomly assigned&#xD;
      to one of the following conditions prior to the assessments: receiving 15mg of dronabinol and&#xD;
      smoking a placebo marijuana cigarette, receiving a placebo pill and smoking a real marijuana&#xD;
      cigarette, or receiving a placebo pill and smoking a placebo marijuana cigarette. Group 4 and&#xD;
      Group 8 will receive no drug or placebo at T2. Participants receiving drug will have safety&#xD;
      assessments before the drug is administered, after the drug is administered but before&#xD;
      leaving the research clinic for the day, and again a week later.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">September 18, 2021</completion_date>
  <primary_completion_date type="Actual">September 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain Reward Circuit Activation</measure>
    <time_frame>3 hours</time_frame>
    <description>Activation of the Brain Reward Circuit (particularly the nucleus accumbens) in anticipation of monetary reward.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting State Connectivity</measure>
    <time_frame>3 hours</time_frame>
    <description>Resting state connectivity within the brain reward circuit</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">261</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Dual Diagnosis</condition>
  <condition>Psychotic Disorder</condition>
  <condition>Cannabis Use Disorder</condition>
  <arm_group>
    <arm_group_label>Marijuana cigarette and placebo capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dronabinol and placebo cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cigarette and placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marijuana</intervention_name>
    <description>Smoked plant with THC</description>
    <arm_group_label>Marijuana cigarette and placebo capsule</arm_group_label>
    <other_name>Cannabis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol</intervention_name>
    <description>Capsule with THC</description>
    <arm_group_label>Dronabinol and placebo cigarette</arm_group_label>
    <other_name>Marinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule with no active ingredient</description>
    <arm_group_label>Placebo cigarette and placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Groups 1-3 Participants with schizophrenia and a cannabis use disorder&#xD;
&#xD;
          1. Ages 18 - 55 years&#xD;
&#xD;
          2. Diagnosis of schizophrenia&#xD;
&#xD;
          3. Diagnosis of cannabis abuse or dependence&#xD;
&#xD;
          4. Use of cannabis within the month prior to screening&#xD;
&#xD;
          5. Willing to remain abstinent for the 14 days before the baseline assessments and&#xD;
             throughout the two scans.&#xD;
&#xD;
          6. Psychiatrically stable&#xD;
&#xD;
          7. Treated with a stable dose of an antipsychotic medication (except clozapine) for the&#xD;
             past month&#xD;
&#xD;
          8. Not seeking treatment for their cannabis use disorder.&#xD;
&#xD;
        Group 4 - Control participants with schizophrenia&#xD;
&#xD;
          1. Ages 18 - 55 years&#xD;
&#xD;
          2. Diagnosis of schizophrenia&#xD;
&#xD;
          3. Willing to remain abstinent as described above&#xD;
&#xD;
          4. Psychiatrically stable&#xD;
&#xD;
          5. Treated with a stable dose of an antipsychotic medication (except clozapine) for the&#xD;
             past month&#xD;
&#xD;
        Groups 5-7 - Control participants with cannabis use disorder&#xD;
&#xD;
          1. Ages 18 - 55 years&#xD;
&#xD;
          2. Diagnosis of cannabis abuse or dependence&#xD;
&#xD;
          3. Use of cannabis within the month prior to screening&#xD;
&#xD;
          4. Willing to remain abstinent as described above&#xD;
&#xD;
          5. Not seeking treatment for their cannabis use disorder.&#xD;
&#xD;
        Group 8 - Healthy control participants&#xD;
&#xD;
          1. Ages 18 - 55 years&#xD;
&#xD;
          2. Willing to remain abstinent as described above&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Groups 1-3 with schizophrenia and a cannabis use disorder&#xD;
&#xD;
          1. Positive symptoms of psychosis (&gt; 4 [moderate]) on any item of the Positive and&#xD;
             Negative Syndrome Scale psychosis subscale (once abstinent) except for the&#xD;
             hallucination item. We will exclude for a rating &gt; 5 for this item.&#xD;
&#xD;
          2. Cocaine/stimulant use disorder&#xD;
&#xD;
          3. Pharmacological treatment for addiction&#xD;
&#xD;
          4. Mental retardation&#xD;
&#xD;
          5. History of head injury&#xD;
&#xD;
          6. Metal objects within the body that would contraindicate and MRI&#xD;
&#xD;
          7. Pregnancy or currently nursing&#xD;
&#xD;
          8. Uncontrolled medical condition&#xD;
&#xD;
          9. Taking clozapine&#xD;
&#xD;
         10. Any condition that would contraindicate use of cannabis or dronabinol.&#xD;
&#xD;
         11. History of a seizure disorder&#xD;
&#xD;
        Group 4 - Control participants with schizophrenia&#xD;
&#xD;
          1. Positive symptoms of psychosis (&gt; 4 [moderate]) on any item of the Positive and&#xD;
             Negative Syndrome Scale psychosis subscale (once abstinent) except for the&#xD;
             hallucination item. We will exclude for a rating &gt; 5 for this item.&#xD;
&#xD;
          2. Any history of a substance use disorder other than nicotine&#xD;
&#xD;
          3. Pharmacological treatment for addiction&#xD;
&#xD;
          4. Mental retardation&#xD;
&#xD;
          5. History of head injury&#xD;
&#xD;
          6. Metal objects within the body that would contraindicate and MRI&#xD;
&#xD;
          7. Pregnancy or currently nursing&#xD;
&#xD;
          8. Uncontrolled medical condition&#xD;
&#xD;
          9. Taking clozapine&#xD;
&#xD;
        Groups 5-7 - Control participants with cannabis use disorder&#xD;
&#xD;
          1. Axis I psychiatric diagnosis other than a cannabis use disorder&#xD;
&#xD;
          2. Taking any psychotropic medication&#xD;
&#xD;
          3. Pharmacological treatment for addiction&#xD;
&#xD;
          4. Mental retardation&#xD;
&#xD;
          5. History of head injury&#xD;
&#xD;
          6. Metal objects within the body that would contraindicate and MRI&#xD;
&#xD;
          7. Pregnancy or currently nursing&#xD;
&#xD;
          8. Uncontrolled medical condition&#xD;
&#xD;
          9. History of a seizure disorder&#xD;
&#xD;
        Group 8 - Healthy control participants&#xD;
&#xD;
          1. Any Axis I psychiatric diagnosis&#xD;
&#xD;
          2. Taking any psychotropic medication&#xD;
&#xD;
          3. Pharmacological treatment for addiction&#xD;
&#xD;
          4. Mental retardation&#xD;
&#xD;
          5. History of head injury&#xD;
&#xD;
          6. Metal objects within the body that would contraindicate and MRI&#xD;
&#xD;
          7. Pregnancy or currently nursing&#xD;
&#xD;
          8. Uncontrolled medical condition&#xD;
&#xD;
          9. Current tobacco smokers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary F Brunette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2013</study_first_submitted>
  <study_first_submitted_qc>October 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Mary F. Brunette, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Dronabinol</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Dual Diagnosis</keyword>
  <keyword>Substance Abuse</keyword>
  <keyword>Cannabis Use Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

